Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Tables)
|
9 Months Ended |
Sep. 30, 2017 |
|---|
| Notes Tables |
|
| Schedule of Franchisor Disclosure [Table Text Block] |
| | | Three Months Ended | | Nine Months Ended | | | | September 30, | | September 30, | | Franchised clinics: | | 2017 | | 2016 | | 2017 | | 2016 | | Clinics open at beginning of period | | | 336 | | | | 280 | | | | 309 | | | | 265 | | | Opened or Purchased during the period | | | 6 | | | | 13 | | | | 35 | | | | 38 | | | Acquired during the period | | | - | | | | - | | | | - | | | | (6 | ) | | Closed during the period | | | - | | | | - | | | | (2 | ) | | | (4 | ) | | Clinics in operation at the end of the period | | | 342 | | | | 293 | | | | 342 | | | | 293 | | | | | Three Months Ended | | Nine Months Ended | | | | September 30, | | September 30, | | Company-owned or managed clinics: | | 2017 | | 2016 | | 2017 | | 2016 | | Clinics open at beginning of period | | | 47 | | | | 61 | | | | 61 | | | | 47 | | | Opened during the period | | | - | | | | - | | | | - | | | | 8 | | | Acquired during the period | | | - | | | | - | | | | - | | | | 6 | | | Closed or Sold during the period | | | - | | | | - | | | | (14 | ) | | | - | | | Clinics in operation at the end of the period | | | 47 | | | | 61 | | | | 47 | | | | 61 | | | | | | | | | | | | | | | | | | | | | Total clinics in operation at the end of the period | | | 389 | | | | 354 | | | | 389 | | | | 354 | | | | | | | | | | | | | | | | | | | | | Clinics licenses sold but not yet developed | | | 105 | | | | 134 | | | | 105 | | | | 134 | | | Executed letters of intent for future clinic licenses | | | 5 | | | | - | | | | 5 | | | | - | | |
| Lease Exit Liability [Table Text Block] |
| Lease exit liability at December 31, 2016 | | $ | 338,151 | | | Additions | | | 883,146 | | | Settlements | | | (706,991 | ) | | Net Accretion | | | (66,030 | ) | | Lease exit liability at September 30, 2017 | | $ | 448,276 | | |
| Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
| | | Three Months Ended | | Nine Months Ended | | | | September 30, | | September 30, | | | | 2017 | | 2016 | | 2017 | | 2016 | | | | | | | | | | | | Net loss | | $ | (403,808 | ) | | $ | (2,626,894 | ) | | $ | (3,062,035 | ) | | $ | (9,413,407 | ) | | | | | | | | | | | | | | | | | | | | Weighted average common shares outstanding - basic | | | 13,262,032 | | | | 12,730,624 | | | | 13,144,764 | | | | 12,657,435 | | | Effect of dilutive securities: | | | | | | | | | | | | | | | | | | Stock options | | | - | | | | - | | | | - | | | | - | | | Weighted average common shares outstanding - diluted | | | 13,262,032 | | | | 12,730,624 | | | | 13,144,764 | | | | 12,657,435 | | | | | | | | | | | | | | | | | | | | | Basic and diluted loss per share | | $ | (0.03 | ) | | $ | (0.21 | ) | | $ | (0.23 | ) | | $ | (0.74 | ) | |
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] |
| | | Three Months Ended | | Nine Months Ended | | | | September 30, | | September 30, | | | | 2017 | | 2016 | | 2017 | | 2016 | | Unvested restricted stock | | | 63,700 | | | | 92,415 | | | | 63,700 | | | | 92,415 | | | Stock options | | | 1,011,686 | | | | 899,370 | | | | 1,011,686 | | | | 899,370 | | | Warrants | | | 90,000 | | | | 90,000 | | | | 90,000 | | | | 90,000 | | |